Erectile dysfunction (ED) is an early marker for systemic atherosclerosis and is a predictor for coronary artery disease and cardiac events. The aim of this paper is to convey the importance of addressing cardiovascular risk factors in patients with ED and to inform urologists as well as other physicians who are not specialized in cardiology how to carry out a basic cardiovascular evaluation, including history, physical examination and objective data. We review the evidence and pathophysiology linking ED to cardiovascular disease, and then describe how to carry out a basic cardiovascular evaluation. We present data from the literature showing that appropriate use of lifestyle modifications and medical therapy has a positive effect on mortality, on numerous cardiovascular end points and on ED. Suggestions of when to refer the ED patient to an internist or cardiologist are provided. Identifying and treating cardiovascular risk factors may not only benefit the patient's ED, but it might also save the patient's life.
Introduction
Erectile dysfunction (ED) affects 30 million men in the United States. As many as 57% of these men are o55 years. 1 ED is now recognized as an early marker for cardiovascular disease; therefore, the patient presenting with ED should undergo a cardiovascular evaluation. This paper briefly reviews the evidence linking ED with cardiovascular disease, and then describes the underlying pathophysiology. A basic approach to cardiovascular evaluation is presented, including history, physical examination and objective data. Evidence supporting a beneficial effect of physical activity and weight loss on ED is reviewed, as is evidence supporting medical therapy for cardiovascular risk factors. Identifying and treating cardiovascular risk factors may not only benefit the patient's ED, but it might also save the patient's life.
Evidence that ED is an early marker of vascular disease
The evidence linking ED with vascular disease is reviewed elsewhere. [2] [3] [4] [5] Briefly, a large epidemiological study 6 and a prospective study 7 reported that ED shares numerous risk factors with vascular disease, including smoking, hypertension, diabetes, dyslipidemia, obesity and metabolic syndrome. A longitudinal survey 8 described the coronary artery disease (CAD) incidence densities per 1000 personyears for men without vs with ED: 0.94 vs 48.52 (40- Although ED had a marked association with CAD in men o60 years, the association seemed to have little prognostic importance in older men. Similarly, the association between ED and diabetes mellitus is strongest for men aged 46-55 years, and this association decreases with older age, 1 which emphasizes the point that ED is a stronger marker for vascular disease in men o60 years. Kaiser et al. 9 investigated vascular parameters in 30 patients with ED and found evidence of penile vascular disease, endothelial dysfunction and impaired endothelialindependent vasodilatation. An accompanying editorial stated that ED is a marker for vascular disease and should alert the physician to the possibility of systemic vascular problems in the future. 10 Morley et al.
11 discovered that patients with ED and an abnormal penile brachial pressure index (PBPI) (o0.65), compared with those with PBPI 40.65, had significantly more myocardial infarctions and cerebrovascular accidents. Vlachopoulos et al. 12 investigated the prevalence of CAD in men whose only complaint was ED and found angiographically silent CAD in 19% (9 of 47), which emphasizes the importance of risk reduction in this high-risk population. Similarly, Pritzker 13 evaluated 50 asymptomatic (cardiac) men who had ED for cardiac ischemia. All 20 patients who underwent coronary angiography had demonstrable disease, and the investigators concluded that men with ED and without cardiac symptoms have a high prevalence of cardiac risk factors and CAD. They likened male sexual function to the penile stress test as a 'window to the hearts of man. ' The aforementioned studies and others [14] [15] [16] [17] [18] comprise an abundance of evidence indicating ED is an early marker for vascular disease. Conversely, ED is highly prevalent in cardiac patients. Kloner et al. 19 investigated sexual function in 76 men with chronic stable CAD and reported that 75% had ED or a recent history of ED. Similarly, 75% of patients with CAD at the Tel-Aviv Sourasky Medical Center had ED. 20 Not only is ED an early marker for vascular disease, but once CAD becomes evident, atherosclerosis has already begun to impair penile blood flow and erectile function in the majority of patients, as will be discussed in the next section.
Pathophysiology behind ED as an early marker of vascular disease
It is now evident that ED is an early warning sign for cardiovascular disease in many patients. This phenomenon results from the effects of atherosclerosis and endothelial dysfunction on the physiology of penile erection. 21, 22 Penile erection is a neurovascular event that involves dilation of the arteries and arterioles that supply the erectile tissue which culminates in a several fold increase in penile blood flow. Atherosclerosis affects the vasculature throughout the entire body. 3 All vascular beds are affected; however, clinical manifestations present at different times. When a lumen obstruction reaches 50-75% it begins to limit flow. 3 Therefore, differing arterial lumen sizes may account for varying clinical presentations. ED may present before manifestations of CAD in some patients because the penile arteries are smaller than the epicardial coronary arteries (typically 0.5-2 mm vs 3-4 mm in diameter). 2, 5, 9, 23 In this way, the smaller penile arteries can be regarded as 'the tip of the iceberg', 3 so that ED is a harbinger of systemic atherosclerosis.
Endothelial cells have an integral role in penile erection and endothelial dysfunction and may also explain the frequent occurrence of ED before overt CAD. 9, 22 Endothelial cells modulate vascular tone and blood flow and are crucial to physiological flow-mediated dilation 9, 24, 25 and penile erection. 9, 16, 26 In contrast, while most conduit arteries dilate B15% during flow-mediated dilation, cavernosal and helicine arteries must dilate up to 80% to sustain an erection. Moreover, to maintain an erection, endothelial-dependent dilation of trabecular smooth muscle and engorgement of the sinusoidal system with blood is necessary to compress the venous system and prevent venous outflow. In contrast, endothelial cells have little role in venous circulation in most other vascular beds. Thus, compared with most vascular processes, penile erection relies heavily on endothelial function for more substantial arterial dilation and for venous compression. 9 As endothelial dysfunction occurs early in the process of atherosclerosis, 9, 24, 25, 27 penile erection may be affected before the development of overt CAD.
Basic cardiovascular evaluation
As ED is an early marker for systemic atherosclerosis 5, 6, 9, 10, [16] [17] [18] and is a predictor for CAD and cardiac events, 8, 11, [13] [14] [15] all patients presenting with ED should be questioned about their cardiovascular health. [2] [3] [4] [5] 28 When a patient presents with ED, especially a younger patient, the clinician has the opportunity to identify modifiable risk factors at an early stage. This section describes the essential elements of a basic cardiovascular evaluation, including history, physical examination and objective data.
History
Patients should be asked about major symptoms associated with cardiac disease, including chest discomfort, dyspnea, fatigue, orthopnea, edema, palpitations and syncope. The differential diagnosis of chest pain can be divided into three broad categories: CAD, cardiac non-CAD and non-cardiac ( Figure 1 ). When evaluating chest discomfort, eliciting the etiology can be facilitated by assessing the following factors: location, radiation, precipitating and alleviating factors, duration and associated symptoms. Typical angina is substernal, exertional, and is described as 'pain' or a sensation of 'pressure', 'squeezing', 'burning', 'aching', 'discomfort' or 'tightness'. Angina typically lasts for a few to several minutes. Pain that lasts only a few seconds or that is fleeting is usually not angina. Conversely, pain that is constant and described by the patient as 'there all the time' is unlikely to be angina. Angina 
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Pleuritic pain often indicates pulmonary or pleural disease, but also results from pulmonary embolism and pericarditis. 29, 30 Chest pain due to CAD may manifest as stable angina, unstable angina or acute myocardial infarction. Stable angina is generally unchanged in frequency over time and represents chronic CAD. Unstable angina often results from erosion of an atherosclerotic plaque and may occur suddenly. Unstable angina may be new angina or angina occurring more frequently and severely with less activity, or angina at rest. Myocardial infarction entails prolonged ischemia usually due to rupture of a plaque with superimposed thrombus preventing distal blood flow and causing myocyte cell death. Unstable angina and myocardial infarction require emergent treatment, whereas stable angina can be routinely relieved with nitroglycerin. Traditionally, the duration of stable angina is considered to be 2-10 min, whereas unstable angina can last a few minutes or up to 30 min, and pain longer than 30 min is either acute myocardial infarction or nonischemic in etiology. Again, pain that lasts for only few seconds or pain that is constant is unlikely to be angina. 29, 30 Palpitations, an awareness of one's own heart beat, may be described using a variety of terms, such as 'flutters', 'skips' or 'pounding', and may indicate an arrhythmia. Palpitations may be associated with other symptoms and it is worth asking if the patient noted dyspnea, dizziness, chest pain, diaphoresis or syncope as well. Cardiac syncope classically has a sudden onset and resolves quickly, restoring full consciousness. In contrast, a prodrome typically precedes neurogenic syncope, which often shows signs of seizure or a prolonged postictal state. Orthostatic syncope results from dehydration, blood loss or extreme vasodilation (which can occur with certain antihypertensive medicines). Orthostatic syncope occurs when sitting up or standing from a laying position (often when the shift in posture is rapid or sudden), and is suggested by orthostatic hypotension, a X20 mm Hg drop in systolic blood pressure or a X10 mm Hg drop in diastolic blood pressure within 3 min of standing. 30 Heart failure usually manifests as dyspnea, orthopnea, fatigue, edema and exercise limitation. Orthopnea is a discomfort in breathing that is brought on or aggravated by lying flat. Paroxysmal nocturnal dyspnea is common in heart failure, usually occurs 2-4 h after onset of sleep (as fluid shifts into the lungs), compels the patient to sit upright or stand, and subsides gradually over several minutes. Lower extremity edema worsens as the day progresses. The extent of exercise limitation should be assessed by the New York Heart Association (NYHA) Functional Classification (Table 1) , because in patients with heart failure, the NYHA class is a strong and independent predictor of mortality. 30 A vascular disorder may manifest as limb pain, edema, skin discoloration, peripheral ulcerations or claudication (a cramping pain in the legs brought on by exertion and relieved by rest). 30 In addition to symptoms, the clinician should inquire about the presence of modifiable cardiovascular risk factors, including diabetes mellitus, hypertension, dyslipidemia, smoking, physical inactivity and obesity. The clinician should also note non-modifiable risk factors, such as male gender, age (male 445 years, female 455 years), and family history of premature CAD (CAD in male first-degree relative o55 years, CAD in female first-degree relative o65 years). Patients should also be asked about their medications. Treatment of ED with phosphodiesterase-5 (PDE5) inhibitors is contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, and so on). Organic nitrates increase the production of cyclic GMP and PDE5 inhibitors prevent the breakdown of cyclic GMP, the substance that promotes relaxation of vascular smooth muscle cells leading to an erection. Combining organic nitrates with PDE5 inhibitors has the potential for systemic vasodilation and frank hypotension. 31 In contrast, sildenafil has proven to be safe and effective for ED in patients with heart Figure 1 A suggested differential diagnosis and method for categorizing patients with chest pain, based on the opinion of the authors. GERD, gastroesophageal reflux disease.
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Physical examination
General appearance is important and may alert the physician to serious disease if the patient is diaphoretic, dyspneic, emaciated or cyanotic. Waist circumference and body mass index should be measured routinely in men with ED. Vital signs, including pulse rate, blood pressure, respiratory rate and oxygen saturation, are important indicators of cardiovascular health. The normal range is generally considered a pulse rate of 60-100 beats per min, blood pressure o140/90 mm Hg, respiratory rate 12-20 breaths per min and oxygen saturation 494%. Hypotension is ill defined with different values reported for various clinical situations, but a blood pressure o90/60 mm Hg should elicit concern. Vital signs significantly outside the normal range may necessitate urgent intervention, especially in a symptomatic patient. Mild abnormalities must also be addressed, albeit less urgently. The first response to abnormal vital signs is to repeat the vital signs, which may normalize after the patient has been sitting, relaxed for several minutes. The asymptomatic patient with hypertension in clinic usually represents chronic hypertension; however, a systolic blood pressure 4180 mm Hg or a diastolic blood pressure 4120 mm Hg defines hypertensive urgency and must be treated immediately. The extremities are examined. Yellow staining of the fingertips suggests smoking; and clubbing, loss of the normal o1651 angle between the nail bed and the fold (cuticle) usually indicates lung disease or cyanotic heart disease. Lower extremity ulcers often result from diabetes mellitus (located at points of increased pressure) or venous insufficiency (usually medial). Bilateral lower extremity edema occurs in many volume-overloaded states, including heart failure, renal failure and hepatic failure, or from dihydropyridine calcium channel blockers (for example, nifedipine, felodipine and amlodipine) secondary to vasodilation of arterioles. Unilateral leg swelling can reflect venous thrombosis, lymphatic obstruction or previous surgery.
The peripheral arterial pulses are palpated and are examined for symmetry and strength, including the radial, femoral and dorsalis pedis. Listen for bruits over the femoral arteries, carotid arteries and abdomen (aorta and renal arteries). Stenotic atheromatous lesions may manifest as weak or asymmetrical peripheral pulses or bruits. Varicose veins in the lower extremities may be associated with a varicocele. 33 The jugular veins are assessed with the patient reclined at 301 from supine position. In this position, a general rule is the level of the clavicle represents 5 cm from the heart and the angle of the mandible corresponds to 12 cm, although values range widely between patients. Right-sided heart failure (and a few other conditions) causes jugular venous distension, venous pulsations (double pulsations) 46 cm (8 mm Hg) from the heart. 30, 34 The lungs are auscultated. Rales (a fine crackly sound), often confined to the bases, suggest congestive heart failure, whereas distant lung sounds with rhonchi (a coarse rattling sound somewhat like snoring) often result from chronic obstructive pulmonary disease. Distant lung sounds confined to the bases usually indicate pleural effusions, but may also result from mass lesions.
Finally, the clinician examines the heart. With the patient reclined at 301 from the supine position, the cardiac point of maximal impulse (PMI), usually located in the mid-clavicular line at the fifth intercostal space, is palpated. Standing on the patient's right with the patient in the left lateral decubitus position may facilitate palpation in obese or muscular patients. Leftward and downward displacement of the PMI results from an enlarged heart, as may occur with valvular disease, dilated cardiomyopathy or previous myocardial infarction. A diffuse and sustained PMI may reflect systolic dysfunction and a dyskinetic apex may reflect a recent myocardial infarction. The heart sounds are auscultated in several locations, including the second intercostal space at both parasternal borders and the fifth intercostal space at the left parasternal border and left midclavicular line, and the apex. Murmurs usually reflect valvular pathology. Murmurs are described in terms of intensity (grade I is very faint, grade II is soft, grade III is loud and grades IV-VI are associated with a thrill), timing (early-, mid-, late-, or holosystolic or diastolic), location on the chest wall where the murmur is loudest, and whether the murmur radiates to another area (axillary or carotids). A cardiac thrill is a palpable Modifying cardiovascular risk in erectile dysfunction BG Schwartz and RA Kloner vibration that accompanies a cardiac murmur and indicates severe pathology. A pathological fourth heart sound (heard just before S1) is common in patients who have CAD or hypertension, whereas a pathological third heart sound (heard just after S2) suggests volume overload or congestive heart failure. 30 Objective data The clinician might investigate a variety of objective data in response to abnormalities in the cardiovascular history and physical examination. In all patients presenting with ED, ordering a fasting glucose, hemoglobin A 1C , lipid panel, creatinine, serum testosterone 35 and electrocardiogram are considered. The electrocardiogram is invaluable in detecting and diagnosing nearly all types of heart disease, including rhythm abnormalities, structural abnormalities, and the extent and severity of myocardial ischemia. Depending on the clinical scenario, additional workup may be indicated. Chest X-rays should be obtained for all patients with cardiac symptoms to assess the heart and chamber size, great vessels, pulmonary vascular redistribution, pulmonary edema, calcification (valves, aorta, vessels) or other pathology. A chest X-ray should also be obtained for patients with respiratory complaints or an abnormal lung examination and most pleural effusions should be aspirated for analysis, except in the patient with bilateral pleural effusions and evidence of congestive heart failure. The possibility of a deep venous thrombosis should be investigated with a lowerextremity Doppler ultrasound for patients with unilateral leg edema without a clear cause. If cardiac syncope or an arrhythmia is suspected but not apparent on electrocardiogram, 24-h electrocardiographic recording or an event monitor may be useful. Evidence suggestive of heart failure or valvular pathology should prompt an echocardiogram, which noninvasively evaluates structural, functional or hemodynamic abnormalities of the heart and great vessels.
Concern for myocardial ischemia should be further evaluated with a cardiac stress test and in some cases a coronary angiogram. Different types of cardiac stress tests use different 'stressors' and different 'evaluators'. Exercise is the preferred 'stressor' and should be used in all patients capable of attaining a sufficient level of exercise, X85% of maximum heart rate (220-age). In addition to estimating the likelihood and extent of CAD, exercise stress testing determines functional capacity, estimates prognosis and predicts the effectiveness of therapies. For patients who are unable to exercise, pharmacological 'stressors' are used. Adenosine and dipyridamole dilate the normal coronary resistance vessels and increase blood flow to vascular distributions supplied by normal coronary arteries. Stenotic vessels, however, show limited or no dilation to adenosine or dipyridamole resulting in relatively low or diminished blood flow to the vascular beds supplied by stenotic coronary arteries. This heterogeneity in myocardial blood flow caused by exercise or pharmacological 'stressors' can be measured with various 'evaluators'. All stress tests should use electrocardiography to assess for myocardial ischemia, which manifests as ST segment displacement. Electrocardiography is often sufficient as an 'evaluator' in patients with low or intermediate likelihood of CAD. However, since electrocardiography stress testing alone has a sensitivity of 68% and a specificity of 77% for detecting CAD, 36 an additional 'evaluator' is often indicated for high-risk patients. For patients with ST segment abnormalities at baseline, electrocardiography is less interpretable and must be supplemented by radionuclide myocardial perfusion imaging. In addition, perfusion imaging is often indicated for patients with a high probability of CAD, previous myocardial infarction, or intermediate electrocardiographic stress test results. Radionuclide myocardial perfusion imaging uses intravenous tracers (thallium, sestamibi) preferentially extracted from the blood by viable myocytes to illustrate areas of normal coronary blood flow, and inversely, tissue with limited or no blood flow. Although nuclear imaging consists of increased risk, time and cost relative to electrocardiography, nuclear testing more accurately determines the location and extent of coronary disease with increased sensitivity and specificity for detecting CAD, and can assess myocardial viability. By comparing stress and rest images, stress echocardiography can be used to determine whether exertional symptoms result from CAD, valvular disease or diastolic dysfunction. Echocardiography as an 'evaluator' is usually combined with the 'stressor' exercise or dobutamine, an adrenergic agonist that increases cardiac contractility, heart rate and oxygen demand, which stimulates increased myocardial blood flow. Multidetector computed tomography (which includes computed tomography angiography) represents a relatively new, relatively noninvasive method of assessing the coronary arteries and has the capacity to identify the presence of early CAD (o50% lumen obstruction). 37 Multidetector computed tomography reports a coronary calcium score, which incorporates the size and density of all calcium deposits in atherosclerotic plaques throughout the coronary vasculature and predicts cardiac events. Using multidetector computed tomography, Jackson and Padley 23 reported an elevated coronary calcium score (450) in 11 out of 20 men with ED and without cardiac symptoms; only two of them had an abnormal exercise electrocardiography stress test. Coronary angiography is the 'gold standard' in evaluating CAD and an experienced interventionalist can deploy various Modifying cardiovascular risk in erectile dysfunction BG Schwartz and RA Kloner therapies directed at diseased vessels. When noninvasive methods are insufficient, cardiac catheterization is recommended to define the presence or severity of a suspected cardiac lesion.
Life-saving interventions
Once the clinician has identified cardiovascular risk factors, achieving treatment goals will drastically reduce patients' cardiovascular morbidity and mortality. Hypertension, diabetes mellitus and dyslipidemia should be controlled with lifestyle modifications and, if necessary, with medications. Smoking cessation, diet and exercise are fundamental to good cardiovascular health, reduce major cardiovascular events and should be recommended to all patients with cardiac risk factors. In addition to controlling cardiovascular risk factors, some evidence supports a beneficial effect of physical activity and weight loss on ED. Numerous large multicenter controlled trials demonstrate the markedly positive effect of medical therapy on a number of cardiovascular end points including mortality.
Lifestyle modifications
Cigarette smoking increases the risk of death from CAD (relative risk ¼ 1.57). 38, 39 and the incidence of ED. 6, 15, 19, 40 Compared with persistent smokers, after 1 year of cessation the risk of death from CAD is reduced (relative risk ¼ 0.63), and is further reduced at 10 years (relative risk ¼ 0.38). 39 Obesity is a risk factor for cardiovascular disease and for ED. 7, 22, 41 Derby et al. 40 evaluated the impact of lifestyle changes on ED through a longitudinal cohort study and concluded that physical activity initiated in midlife may reduce the risk of ED. In a related study, Esposito et al. 42 conducted a randomized, single-blind trial of 110 obese men aged 35-55 years, with ED and without diabetes mellitus, hypertension or hyperlipidemia. The 55 men in the intervention group received detailed advice about how to achieve weight loss through diet and exercise and showed improvement compared with the control group after 2 years: greater decrease in body mass index (5.7 vs 0.7, Po0.001), more physical activity (195 vs 84 min per week, Po0.001), significant improvement in ED by improved mean score on questions 1-5 of the International Index of Erectile Function (IIEF) test (13.9-17.0, Po0.001), and more men no longer met ED criteria with a score X22 on questions 1-5 of the IIEF test (17 vs 3 men, P ¼ 0.001). In multivariate analysis, changes in body mass index (P ¼ 0.02) and physical activity (P ¼ 0.02) were independently associated with changes in the IIEF score (questions 1-5). It was concluded that about one-third of obese men with ED at baseline were able to improve sexual function through lifestyle changes.
Medical therapy
When lifestyle modifications are insufficient to control disease, medical therapy for diabetes, hypertension and dyslipidemia markedly and significantly affect an array of cardiovascular end points.
Diabetes mellitus is considered a CAD equivalent and its management, beginning with diet and weight loss, is essential to improving cardiovascular health. Two separate fasting plasma glucose levels of 126 mg per 100 ml or higher is diagnostic of diabetes mellitus. An elevated hemoglobin A 1C (normal range 4-6%) is not considered diagnostic, but is highly suggestive of diabetes mellitus. 43 The degree of hyperglycemia, as measured by hemoglobin A 1C , correlates with increased incidences of CAD and peripheral arterial disease. 44 Moreover, hemoglobin A 1C independently predicts the presence of ED and the degree of ED among patients with diabetes mellitus. 27 Improved glucose control protects against microvascular complications. 45, 46 Early initiation of intensive glucose control reduces the risk of macrovascular events and death; 46 however, delayed initiation of intensive glucose control does not reduce macrovascular events 45 and even increased mortality in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. 47 Again, this underscores the importance of early detection and initiation of therapy for diabetes and other cardiovascular risk factors. Diabetes therapy should target a hemoglobin A 1C of p7%, with a lower target for selected patients for primary prevention of macrovascular disease. 45 Low-density lipoprotein (LDL) cholesterol is the primary target of cholesterol lowering therapy and LDL goals vary depending on the number of cardiac risk factors, which include smoking, hypertension (blood pressure X140/90 mm Hg or on antihypertensive medication), low high-density lipoprotein cholesterol (o40 mg per 100 ml), age (men X45 years, women X55 years) and family history of premature CAD (CAD in male first-degree relative o55 years, CAD in female first-degree relative o65 years). LDL treatment goals are o70 mg per 100 ml for patients with CAD and a history of an acute coronary syndrome; 48 o100 mg per 100 ml for patients with CAD, systemic atherosclerosis or diabetes mellitus; o130 mg per 100 ml for patients with X2 cardiac risk factors; and o160 mg per 100 ml for patients with 0-1 cardiac risk factor. 49 The use of statins lowers LDL levels by 30-40% that translates to a similar reduction in risk for major coronary events of 30-40% over 5 years. 49 Case reports 50 and an observational study 51 implicated statins as a cause of ED. However, these reports lacked control patients and the nature of ED introduced potential bias as patients are eager to
Modifying cardiovascular risk in erectile dysfunction BG Schwartz and RA Kloner blame external factors. 52 A different observational study 53 suggested that atorvastatin improves ED, whereas Castro et al. 54 showed that atorvastatin enhanced the effects of sildenafil through an endothelium-dependent nitric oxide mechanism. Randomized controlled trials 50, 52 have not shown a significant difference between statins and placebo in relation to ED. Although the affect of statins on ED is unknown, if a patient reports ED in relation to statin therapy, it is reasonable to prescribe a different class of lipid-lowering drug or a different statin. 50 Regarding cardiovascular disease, two large randomized trials, the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) and the Collaborative Atorvastatin Diabetes Study (CARDS), were designed to evaluate statin therapy as primary prevention in patients who were not considered dyslipidemic, but had hypertension or diabetes, respectively. Each trial was stopped early because of a highly significant reduction in major cardiovascular and cerebrovascular events in the statin group. These trials likely included a significant number of men with ED, which emphasizes the importance of cardiovascular risk reduction in this high-risk group. 5 The benefits of lowering blood pressure in patients with hypertension have been shown in numerous large-scale studies. [55] [56] [57] Treatment with any commonly used antihypertensive reduces the risk of total major cardiovascular events, stroke, CAD, heart failure, cardiovascular death and total mortality; and a greater reduction in blood pressure is directly associated with greater reductions in risks of stroke, CAD, major cardiovascular events, cardiovascular death and total mortality. [55] [56] [57] Another large-scale analysis of cohort studies and randomized trials reported that a 5 mm Hg reduction in blood pressure, from any baseline blood pressure level, reduces the risk of stroke by 34% and ischemic heart disease by 21%. 58 Blood pressure goals are o140/90 mm Hg for patients with few other risk factors, o130/80 mm Hg for patients with diabetes mellitus or chronic kidney disease and o120/80 mm Hg for high-risk patients with a history of cardiovascular events.
Erectile dysfunction is more prevalent in patients with untreated hypertension than in normotensive controls. 59 Although no study has shown that lowering blood pressure benefits ED, one study of 101 hypertensive outpatients showed that impotent patients had higher systolic blood pressures and a higher World Health Organization hypertension stage than potent hypertensives. 60 Contrary to improving ED symptoms, several antihypertensive agents have been implicated in causing sexual side effects, including thiazide diuretics, b-blockers, spironolactone and clonidine, although direct supporting evidence is limited and conflicting. 59 The high prevalence of ED associated with hypertension and with antihypertensive medications underscores the importance of inquiring about sexual function before initiating therapy. Sexual side effects are frequently cited by patients as the reason for discontinuing medications. If a patient reports that sexual function worsens after initiation of an antihypertensive medication, the medication should be discontinued and replaced with an agent with a different mechanism. If sexual function returns, the medication can be assumed to have caused the dysfunction. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blockers are suggested to have less deteriorating effects on erectile function. [59] [60] [61] In addition, the metabolic syndrome predicts ED, the severity of ED 7 and cardiovascular disease. 62 The metabolic syndrome (syndrome X) consists of a constellation of risk factors commonly clustered together. According to the Adult Treatment Panel III, the diagnosis of metabolic syndrome is made when 3 of 5 criteria are met: (i) waist circumference 4102 cm for men (488 cm for women), (ii) triglycerides X150 mg per 100 ml, (iii) high-density lipoprotein o40 mg per 100 ml for men (o50 mg per 100 ml for women), (iv) blood pressure X130/85 mm Hg and (v) fasting glucose X110 mg per 100 ml. Obesity is the primary target of therapy for metabolic syndrome, therefore clinicians should encourage weight loss through diet and exercise. Also, blood pressure should be controlled as previously discussed, and statins should be prescribed to reduce the risk for cardiovascular events for patients with the metabolic syndrome. If the patient also meets criteria for diabetes, then glucose should be controlled with medications.
Referrals
In some patients, referral to an internist or cardiologist may be indicated if the patient is not already followed by someone. A general internist is capable of managing most clinic patients and will consult a cardiologist when necessary. Table 2 presents general principles to guide appropriate referrals and represents the opinion of the authors.
Summary
Erectile dysfunction is an early marker for systemic atherosclerosis and predicts CAD and cardiac events; thus, all patients presenting with ED should undergo a basic cardiovascular evaluation. Patients with ED should be encouraged to adopt a healthy lifestyle, including smoking cessation, and weight loss through diet and exercise. Identifying and modifying cardiovascular risk factors is a simple way to make a major impact on morbidity and mortality in the high-risk population with ED. These lifestyle changes may not only improve the patient's sex life, but it may also save their life.
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